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Introduction
Normal embryonic development requires a finely co-ordinated process of temporal and spatial gene expression which is controlled through epigenetic mechanisms (1, 2) . Prenatal dysregulated expression of key developmental genes can lead to specific clinical phenotypes, such as MLH1 and FMR1 repression in hereditary non-polyposis colon cancer and in fragile X syndrome respectively (3) . In addition, aberrant epigenetic mechanisms also have been implicated in the pathogenesis of a diverse range of malignancies (4) .
During vertebrate development, mesoderm specification is tightly regulated by the prototypical T-box transcription factor T (TBXT, also known as T, and brachyury) which through exquisitely orchestrated caudo-cranial morphogenic gradients, controlled through FGF and Activin signalling, ultimately transforms the nascent dorsal mesoderm into the rudimentary axial skeleton, the notochord (5) (6) (7) . TBXT is silenced in the human fetus at approximately 12 weeks and consequentially the notochord recedes prenatally. In embryonic stem cells and mesodermderived differentiating adipogenic cells, regulation of TBXT gene expression is achieved through epigenetic regulatory mechanisms. These include the action of lysine demethylases, in particular lysine demethylase 6A (KDM6A, also known as UTX) and lysine demethylase 6B (KDM6B, JMJD3) (hereafter referred to as KDM6A/B) both demethylases of tri-methylated histone 3 lysine 27 residues (H3K27me3) (8, 9) , the recruitment of histone deacetylase 1 (HDAC1) (10) and CpG island methylation (11, 12) .
In adult tissue aberrant TBXT expression is seen in chordoma, a rare cancer of the axial skeleton showing notochordal differentiation (13, 14) , in the benign notochordal cell tumour, -the precursor of chordoma, and in the haemangioblastoma a rare tumour reminiscent of the embryonic hemangioblast. Individuals diagnosed with chordoma have a median of 7 years 4 4
survival, and they have seen little benefit from genomic studies seeking tractable therapeutic targets such as protein kinases (15) . Small molecule-focused compound screens against chordoma cell lines in vitro have also yielded limited success with few compounds showing inhibition of cell growth: EGFR inhibitors were one of the rare exceptions, results which have led to a phase 2 clinical trial (16, 17) . Although encouraging, this treatment is unlikely to benefit all patients as not all cell lines were responsive, and the rapid development of resistance to EGFR inhibitors in clinical practice is widely documented (18) .
TBXT plays a pivotal role in the development of chordoma (19) . Specifically, TBXT expression is seen in chordoma but is silenced in other tumours of mesodermal origin (20) . At a genomic level germline tandem duplication of TBXT is a key genetic predisposition event in familial chordoma (21) , and 97% of patients with sporadic chordoma harbour the rs2305089 SNP within the DNA binding domain of TBXT conferring a significantly increased risk of developing the disease (22) . Furthermore, at a functional level, TBXT acts as a master regulator of an elaborate oncogenic transcriptional network (19) and its silencing in chordoma cell lines in vitro causes growth arrest (23, 24) . Despite this substantial body of evidence demonstrating that TBXT expression confers oncogenic properties in chordoma, the key mechanisms for regulating its expression have not been reported. This cannot be accounted for by the somatic copy number gain of TBXT as this is only observed in up to 27% of the sporadic cases (15) . In this study we set out to investigate the epigenetic regulation of TBXT in chordoma using a focused library of mechanistically defined inhibitor tool compounds with the aim of identifying vulnerable signalling pathways, which could be exploited for the development of novel treatments for this disease.
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Results
H3K27 demethylases regulate cell viability in chordoma
To identify epigenetic processes of biological importance in chordoma, we screened a library of tool compounds (Dataset S1) (25) targeting proteins involved in chromatin biology including several components of epigenetic readers, writers and erasers of a 'histone' or 'chromatin code', against five well characterised chordoma cell lines (www.chordomafoundation.com). A resazurin-based viability assay was used as the primary anti-proliferative readout (Fig. 1A) .
Decreased cell viability was observed in all cell lines in response to HDAC inhibitors as previously reported (26) . Broad-spectrum inhibitors of the Jmj-type of lysine demethylases were seen to reduce cell viability, as was the more specific inhibitor of KDM6A/B GSK-J4 (27) ( Fig.   1A-B ) but not the regio-isomer control compound GSK-J5, an observation that led us to focus or investigations on the inhibitors of H3K27 demethylases. Decreased viability was also observed with KDOBA67, a novel cell-permeable hydroxyl derivative of GSK-J4 that does not require activation by intracellular esterases (Fig. 1A-B To confirm that the observed inhibitory growth effects with the tool compounds were due to ontarget inhibition of KDM6A/B, we used the CRIPSR/Cas9 system to introduce non-sense mutations in both KDM6A and KDM6B genes ( Fig. S3A-B ). Targeting either gene alone was not sufficient to reduce cell viability but cells in which both genes had been edited showed a significant (p-value < 0.0001) decrease in viability and proliferation ( Fig. 1H and Fig. S3C-G) .
The requirement for inactivation of both KDM6A/B is supported by the finding that the cell line 6 6
MUG-Chor which contains a biallelic deletion of KDM6B only required CRISPR/Cas9 inactivation of KDM6A ( Fig. S3F-H) .
TBXT expression is regulated by H3K27 demethylases
Given the central role of TBXT in chordoma biology, we next asked whether inhibition of KDM6A/B would effect expression of TBXT in chordoma cell lines. Western blot and qPCR analysis confirmed that treatment with either GSK-J4 or KDOBA67, but not with the control compound GSK-J5, reduced TBXT in all chordoma cell lines tested ( Fig. 2A-B Fig. 2E and Fig. S3I ).
Inhibition of KDM6A/B alters the chromatin state at the TBXT locus
To investigate whether the inhibition of KDM6A/B regulates TBXT epigenetically, and reflects the effect of ablation of these genes in development (8, 9) , we examined the distribution of histone marks and histone variants surrounding the TBXT locus in chordoma cell lines. ChIP-PCR demonstrated enrichment of H3K4me3 and H3.3, chromatin marks associated with active gene transcription, at the TBXT promoter in 3 chordoma cell lines known to express TBXT but not in the osteosarcoma cell line U2OS that does not express TBXT (Fig. 3A-B) . In contrast, the repressive marks H3K27me3 and H3K9me2 were enriched in the osteosarcoma cell line but not in the chordoma cells ( Fig. 3C-D) . Examination of DNA methylation at the TBXT locus showed consistent low methylation in the promoter region and at the transcription start site not only in 7 7
primary chordoma tumours (n=35) but also in a range of primary bone tumours and primary solid tumours that are known not to express TBXT ( Fig. 3E and Fig. S4 ). These data imply that alteration in promoter DNA methylation does not play a significant role in the regulation of TBXT in chordoma and a range of malignancies.
To investigate further the chromatin landscape surrounding TBXT and the global changes induced by inhibition of KDM6A/B, we performed quantitative ChIP-seq of H3K27me3 and H3K4me3 marks. Treatment with KDOBA67 led to an increase in H3K27me3 and a decrease in H3K4me3 levels at the TBXT locus ( Fig. 3F) , and these findings were associated with significantly decreased expression of TBXT as assessed by RNAseq ( Fig. 3F and Dataset S2;
H3K27me3 demethylase inhibitor treatment leads to genome-wide alterations in H3K4 and
H3K27 methylation
Methylation of histone residues is a ubiquitous post-translational modification, and inhibition of a demethylase would be expected to have a broad response as opposed to a targeted effect on a single gene. We analysed the distribution of H3K4me3 and H3K27me3 throughout the genome at 48 hours after exposure to KDOBA67 and found there was global suppression of the level of H3K4me3 with a global increase in the level of H3K27me3 ( Fig. 4A-B) . Treatment with KDM6A/B inhibitors did not lead to a change in the location of H3K4me3 peaks but rather to a global decrease in levels of H3K4me3 ( Fig. 4B) . As reported previously for GSK-J4 (28) we also found that KDOBA67 exerts some inhibitory activity in vitro against KDM5 (JARID1) enzymes, the principal H3K4me3 demethylases ( Table S1 ). The observed decrease in H3K4me3 levels in our cell-based experiments is in stark contrast to the reported effect of specific 8 8
H3K4me3 demethylase inhibitors which lead to a global cellular increase in H3K4me3 (29, 30) .
This indicates that the phenotypic response observed in our experiments is the result of the inhibition of KDM6A/B and not an off-target effect against KDM5 enzymes. 4C ), affected pathways are linked to chordoma biology (19) and related to cell movement, adhesion, extracellular matrix organisation, cell contact and signaling (Fig. 4E) . Importantly, this analysis reveals enrichment in categories such as apoptosis, mitochondrial impairment, cell cycle arrest and mitosis ( Fig. 4E) with key genes such as AURK, DUSP10 or the ATF4/DDIT3target gene CHAC1 being identified ( Fig. 4D and Fig. S5 B-E) , findings which are consistent with the obtained anti-proliferative results (Fig. 1) .
Inhibition of KDM6A/B reveals critical pathways for chordoma survival
Treatment of primary chordoma cells with KDOBA67 revealed a similar transcriptomic response
to that seen in chordoma cell lines with increases in ATF4/DDIT3-target genes as measured by qPCR ( Fig. 4F-G and Fig. S6A-B) . The observation of an ATF4-driven stress response is in keeping with data observed in our previous studies and that of others, of the transcriptomic 9 9
response to KDM6 inhibitors in human NK cells and neuroblastoma cells respectively (25, 32) .
As the ATF4-driven stress response leads to a global inhibition of translation as a mechanism for escaping diverse stressors (33) , we set out to determine if the effect seen on expression of TBXT was a primary effect of KDM6 inhibition or if it occurred as a consequence of the induction of the stress response. Time course experiments looking at the expression of TBXT and the markers of the ATF4 response demonstrated that the expression of TBXT begins to decrease prior to the upregulation of genes associated with the ATF4 response ( Fig. 4H and Fig. S6C-D) . To investigate this observation further, we treated chordoma cells with ISRIB (34), a compound that inhibits the induction of the ATF4 response by interfering with eIF2α phosphorylation: ISRIB did not prevent the downregulation of TBXT induced by KDOBA67 ( Fig. 4I-J 
Discussion
In this work we have identified that inhibition of H3K27 demethylases by KDOBA67, a derivative of the previously reported H3K27 demethylase inhibitor, GSK-J4, induces suppression of the embryonic transcription factor TBXT through a global increase of the repressive post-translational modification H3K27me3, followed by apoptosis of chordoma cells.
The results highlight several important aspects in chordoma and epigenetic biology.
From a potential therapeutic standpoint, the number of small molecules that induce significant anti-proliferative effects in chordoma cells is limited (16) . To our knowledge, this is the first time that such a compound has been shown consistently to induce cell death across a number of chordoma cell lines and to reduce simultaneously expression of TBXT. Previously, we and others have shown that treatment with EGFR inhibitors lead to decreased chordoma cell viability (16, 17, 35) , however, the results are variable across different cell lines, and reduction of TBXT expression was seen in response to only one EGFR inhibitor, afatinib (16, 17) . The finding that suppression of TBXT expression and reduced cell survival by H3K27 demethylase inhibition occurred in all tested chordoma cell lines and 4 genomically heterogeneous primary chordoma samples provides compelling evidence that the cellular response to the employed tool compound is consistent. Furthermore, the data imply that any chordoma expressing TBXT is likely to show similar responses to H3K27 demethylase inhibitors due to epigenetic deregulation of the TBXT locus.
With TBXT being implicated in playing a fundamental role in the pathogenesis of chordoma, and apparently being expressed only by neoplastic cells in adult life, it appears to be an ideal therapeutic target (14, 15, 19, 21, 24, 36) . Recognition of this is supported by the development of TBXT-specific poxviral vaccine not only for the treatment of chordoma but also for the minority of cases in which TBXT is expressed in more common cancers where it is supposedly involved in neoplastic epithelial-mesenchymal transition (37) . The challenge in delivering a therapeutic agent is that transcription factors such as TBXT are often considered "undruggable" (38) . However, our data show that it is feasible to block the function of TBXT in chordoma cells indirectly by decreasing its expression via manipulation of the chromatin environment. This strategy has been successfully used for targeting e.g. c-Myc with epigenetic BET bromodomain inhibitors such as JQ1 (39) .
Understanding the mechanisms by which TBXT is expressed in chordoma is critical to understanding this disease. Previous work has implicated DNA promoter methylation in the expression programming of TBXT in development (40) . However, our data show that the promoter region of TBXT shows low methylation not only in chordoma samples, but also in a range of sarcomas in which TBXT is not expressed, implying that low methylation of the TBXT promoter is not sufficient to drive gene expression. Our finding that KDM6A/B inhibition increases H3K27me3 levels, presumably leading to Polycomb Repressive Complex-mediated silencing of gene expression, provides further evidence that lysine demethylases are implicated in the physiological processes of silencing TBXT during embryonic development (8, 9) .
Our study provides further insight into H3K27 demethylase functions in human tumour biology. KDM6/H3K27 demethylases possess in addition to their catalytic subunit additional domains that mediate protein-protein interactions (41) . Since a non-enzymatic scaffolding function of H3K27 demethylases is necessary for developmental effects observed in mesoderm and vertebrate development (8, 9) , and also to T-box transcription factor activity (42) , it is of fundamental interest that inhibition of the enzymatic demethylase functions in the context of chordoma survival is sufficient to control tumour cell proliferation. Furthermore, the inhibitory effect on TBXT expression and associated cell death in response to TBXT gene silencing is only recapitulated by a concerted knockdown of both KDM6A and KDM6B genes. This significant overlap of chemical and genetic perturbations points to synergistic functions for both H3K27 demethylases in regulating the repressive chromatin environment in chordoma, and supports the cooperative function of KDM6A and KDM6B in maintaining the oncogenic expression of TBXT in chordoma.
In contrast to the cooperative function of KDM6A and KDM6B enzymes in chordoma, singular or even opposing roles of KDM6 enzymes have been noted in other malignancies. Whereas KDM6A is considered a tumour suppressor in many instances (43) , KDM6B has been identified as oncogenic driver, e.g. in T-cell acute lymphoblastic leukaemia, controlling Notch1 and its target gene network (44) . Knockdown experiments in chordoma cell lines have revealed that TBXT orchestrates a network of genes involved in the regulation of the cell cycle, in the production of extracellular matrix, growth factor and cytokine secretion, which are necessary for the survival of chordoma cells (19) and pertinent to notochord formation (16, 19) , all of which are downregulated by KDOBA67 treatment. Novel in this scenario is the discovery of possible pro-apoptotic effects observed upon H3K27 demethylase inhibition leading to an ATF4-and DDIT3-driven stress response and highlighting this pathway as a possible therapeutic option in a range of different cancers (33) .
In conclusion, our study provides evidence that H3K27 demethylases are major drivers in the maintenance of the oncogenic expression of TBXT in chordoma. In addition, we show that inactivation of H3K27 demethylases alters the expression of pathways critical to the survival of cancer cells, opening the road to further studies addressing this pathway as a potential molecular target. Detailed methods regarding the synthesis of the KDOBA67 compound, IC50 determination of GSK-J1 analogs, structure determination of KDM6C in complex with KDOBA67 (protein crystallisation, X-ray data collection and structure determination) are available in SI Materials and Methods and Fig. S1 , Table S1-S2.
Materials and Methods
Apoptosis and cell cycle studies, immunoblotting, qPCR, immunofluorescence. Cell cycle analysis was performed using Propidium Iodide (PI) staining, and apoptosis was determined by detecting phosphatidylserine by APC-conjugated Annexin V using flow cytometry as described in SI Materials and Methods. Immunoblotting and qPCRs were performed as described previously (16) . Antibodies and primers are listed in Table S3 and Table S4 respectively.
Immunofluorescence of primary chordoma cells was performed as described previously (45) using antibodies listed in Table S3 . CRISPR/Cas9 knockdown. Target guide sequences validated against KDM6A or KDM6B were designed as previously published (46, 47) . Guides were cloned in a CRISPR/Cas9 lentiviral backbone containing a Puromycin or a Blasticidin resistance cassette, respectively, as described previously in Shalem et al (48) , and cell proliferation following genomic editing was assessed as Figure 4 
